Study of Cardiovascular Disease Risk and Treatment Effects in Women Aged 18 to 45 With or Without Endometriosis

What this Trial Is About

Researchers are studying the increased risk of cardiovascular disease in women with endometriosis. The research aims to understand how estrogen suppression treatments may worsen endothelial dysfunction and chronic inflammation linked to this risk, focusing on the role of the LOX-1 receptor. This trial is an early phase 1 interventional study involving women aged 18 to 45 years. Participants include women with diagnosed endometriosis and healthy control women with regular menstrual cycles. The study evaluates the effects of a drug called Elagolix, taken orally at 400 mg per day for four days. Control participants will not have symptoms or history of endometriosis. The groups are compared without random assignment or masking. During the study, participants will undergo tests including flow mediated vasodilation and microvascular skin blood flow analysis, as well as microdialysis perfusions to assess vascular function. Researchers will monitor cardiovascular and endothelial function to understand disease mechanisms and the impact of estrogen suppression. The study includes careful selection and exclusion criteria and will continue until the end of 2026.

Cardiovascular Disease Risk in Women With Endometriosis